ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559 · ALX Oncology Inc.
PhaseRecorded edit
− Previous value
PHASE1, PHASE2
+ Updated value
PHASE2
ALXO
ALX Oncology Inc.
Company identity has not yet been verified
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
4Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)NCT04675294 | ALX Oncology Inc. | Phase 2 | Active not recruiting | 2025-03-03Actual |
| Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)NCT04675333 | ALX Oncology Inc. | Phase 2 | Active not recruiting | 2025-03-03Actual |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)NCT05002127 | ALX Oncology Inc. | Phase 2, Phase 3 | Active not recruiting | 2024-05-24Actual |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559 | ALX Oncology Inc. | Phase 2 | Recruiting | 2027-12Estimated |
Latest recorded trial changes
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559 · ALX Oncology Inc.
Primary completion dateRecorded edit
− Previous value
2027-06
+ Updated value
2027-12
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559 · ALX Oncology Inc.
Enrollment · participant countRecorded edit
− Previous value
count: 80; type: ESTIMATED
+ Updated value
count: 120; type: ESTIMATED
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559 · ALX Oncology Inc.
Primary outcomes · main study measuresText edit · unverified significance
− Previous value
measure: MBC substudy: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment
+ Updated value
measure: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment
Check registry source · The saved outcome text may be shortened. Check the source for full wording.